LM
VTGN icon

Luminus Management’s VistaGen Therapeutics VTGN Stock Holding History

Luminus Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$226K Buy
396,053
+46,053
+13% +$28K 0.14% 22
2025
Q4 		$232K Buy
+350,000
New +$1.26M 0.2% 20

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Luminus Management's VTGN Position: Q1 2026 in Review

Luminus Management increased its VistaGen Therapeutics (VTGN) stake by 13% in Q1 2026, buying an estimated $28K and bringing the position to 396,053 shares worth $226K. The position accounts for 0.14% of the portfolio, ranked #22.

Luminus Management first reported a position in VTGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $232K in Q4 2025. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Luminus Management held 396,053 shares of VistaGen Therapeutics worth $226K as of Q1 2026.
  • Luminus Management bought 46,053 VistaGen Therapeutics shares in Q1 2026, an estimated $28K.
  • VistaGen Therapeutics made up 0.14% of Luminus Management's portfolio in Q1 2026, its #22 holding.
  • Luminus Management first reported a position in VistaGen Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Luminus Management's VistaGen Therapeutics position peaked at $232K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Luminus Management's 13F filing for Q1 2026, filed 15 May 2026.